Mereo BioPharma Group plc
MREO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $500 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $1 | $132 | $0 | $271 |
| Gross Profit | -$1 | $368 | $0 | -$271 |
| % Margin | – | 73.6% | – | – |
| R&D Expenses | $3,824 | $5,373 | $3,930 | $8,739 |
| G&A Expenses | $6,045 | $5,494 | $7,272 | $0 |
| SG&A Expenses | $6,045 | $5,494 | $7,272 | $6,123 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $145 | $0 | $0 | $0 |
| Operating Expenses | $10,014 | $10,867 | $11,202 | $14,862 |
| Operating Income | -$10,015 | -$10,499 | -$11,202 | -$15,133 |
| % Margin | – | -2,099.8% | – | – |
| Other Income/Exp. Net | $2,991 | -$4,117 | -$1,685 | $7,582 |
| Pre-Tax Income | -$7,024 | -$14,616 | -$12,887 | -$7,551 |
| Tax Expense | $0 | $0 | $0 | -$571 |
| Net Income | -$7,024 | -$14,616 | -$12,887 | -$6,981 |
| % Margin | – | -2,923.2% | – | – |
| EPS | -0.05 | -0.093 | -0.082 | -0.045 |
| % Growth | 45.9% | -12.8% | -82.2% | – |
| EPS Diluted | -0.05 | -0.093 | -0.082 | -0.045 |
| Weighted Avg Shares Out | 159,989 | 159,887 | 156,856 | 155,146 |
| Weighted Avg Shares Out Dil | 159,989 | 159,887 | 156,856 | 155,146 |
| Supplemental Information | – | – | – | – |
| Interest Income | $501 | $589 | $659 | $881 |
| Interest Expense | $28 | $24 | $180 | $375 |
| Depreciation & Amortization | $54 | $298 | $270 | $271 |
| EBITDA | -$9,815 | -$14,294 | -$12,437 | -$6,908 |
| % Margin | – | -2,858.8% | – | – |